Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
WVE Stock Forecast 2026-2027
$6.00
Current Price
$1.15B
Market Cap
Buy 16
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to WVE Price Targets
+616.7%
To High Target of $43.00
+208.3%
To Median Target of $18.50
+100.0%
To Low Target of $12.00
WVE Price Momentum
+3.8%
1 Week Change
-11.4%
1 Month Change
-12.4%
1 Year Change
-64.7%
Year-to-Date Change
-72.4%
From 52W High of $21.73
+19.5%
From 52W Low of $5.02
📊 TOP ANALYST CALLS
Did WVE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if WaVe is one of their latest high-conviction picks.
Latest WVE Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, WVE has a bullish consensus with a median price target of $18.50 (ranging from $12.00 to $43.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $6.00, the median forecast implies a 208.3% upside. This outlook is supported by 16 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
WVE Analyst Ratings
16
Buy
0
Hold
0
Sell
WVE Price Target Range
Low
$12.00
Average
$18.50
High
$43.00
Current: $6.00
Latest WVE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for WVE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 20, 2026 | Wells Fargo | Benjamin Burnett | Overweight | Maintains | $14.00 |
| May 19, 2026 | HC Wainwright & Co. | Andrew S. Fein | Buy | Maintains | $13.00 |
| May 4, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Apr 30, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Apr 29, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| Apr 14, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 27, 2026 | B of A Securities | Buy | Maintains | $N/A | |
| Mar 27, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Mar 25, 2026 | Mizuho | Outperform | Maintains | $N/A | |
| Mar 10, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Mar 6, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Mar 2, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 12, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Feb 5, 2026 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Feb 3, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Dec 19, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Dec 16, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Dec 15, 2025 | Truist Securities | Buy | Maintains | $N/A | |
| Dec 12, 2025 | B. Riley Securities | Buy | Maintains | $N/A | |
| Dec 12, 2025 | Wedbush | Outperform | Maintains | $N/A |
Wave Life Sciences Ltd. (WVE) Competitors
The following stocks are similar to WaVe based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
WVE
WaVe Life Sciences
mkt cap
1.13B
Wave Life Sciences Ltd. (WVE) Financial Data
Wave Life Sciences Ltd. has a market capitalization of $1.15B with a P/E ratio of -5.0x. The company generates $71.80M in trailing twelve-month revenue with a -255.7% profit margin.
Revenue growth is +316.9% quarter-over-quarter, while maintaining an operating margin of -81.8% and return on equity of -53.1%.
Valuation Metrics
Market Cap
$1.15B
Enterprise Value
$600.39M
P/E Ratio
-5.0x
PEG Ratio
0.1x
Price/Sales
15.7x
Growth & Margins
Revenue Growth (YoY)
+316.9%
Gross Margin
N/A
Operating Margin
-81.8%
Net Margin
-255.7%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+47.2%
Current Ratio
11.3x
Debt/Equity
3.1x
ROE
-53.1%
ROA
-28.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Wave Life Sciences Ltd. (WVE) Business Model
About Wave Life Sciences Ltd.
What They Do
Biotechnology company focused on RNA medicines.
Business Model
The company develops RNA-targeted therapeutics using its proprietary PRISM platform, which incorporates various RNA-modulating techniques and insights from genetics. It generates revenue through the advancement of its clinical programs and potential partnerships in the biotechnology sector.
Additional Information
Wave Life Sciences Ltd. was founded in 2012 and is headquartered in Cambridge, Massachusetts, with operations in Singapore. Its pipeline includes treatments for conditions such as Alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy, positioning it as a key player in precision medicine for genetic disorders.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
287
CEO
Dr. Paul B. Bolno M.B.A., M.D.
Country
Singapore
IPO Year
2015
Website
wavelifesciences.comWave Life Sciences Ltd. (WVE) Latest News & Analysis
Latest News
Quick Summary
Wave Life Sciences Ltd. (WVE) presented at the Goldman Sachs 47th Annual Global Healthcare Conference, discussing its developments and strategies.
Why It Matters
Wave Life Sciences' presentation at a major healthcare conference signals potential insights into its pipeline and strategies, impacting investor sentiment and future stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Wave Life Sciences Ltd. will participate in two investor conferences in June 2026, focusing on RNA medicines and their potential in transforming health.
Why It Matters
Wave Life Sciences' participation in investor conferences signals potential growth and interest in its RNA medicines, which could influence stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Johnson Fistel, PLLP is investigating Wave Life Sciences Ltd. (NASDAQ: WVE) for potential violations of federal securities laws related to investor losses.
Why It Matters
The investigation into Wave Life Sciences could indicate potential legal issues and financial losses, affecting stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Wave Life Sciences Ltd. held a shareholder/analyst call, discussing company updates and future strategies. Details from the call may impact investor sentiment and stock performance.
Why It Matters
The transcript provides insights into Wave Life Sciences' performance, strategy, and future outlook, influencing investor sentiment and potential stock price movements.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
WVE-006 shows promise for treating lung and liver issues related to AATD, offering a durable and safe therapy with monthly dosing that mimics the protective MZ-like phenotype.
Why It Matters
WVE-006 shows promise for treating AATD, suggesting a strong market opportunity and potential revenue growth for the company, impacting its stock attractiveness.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A new sponsorship aims to enhance strategies for consistently detecting a genetic, irreversible condition in patients with liver and lung diseases in Durham, N.C.
Why It Matters
The sponsorship indicates potential growth in healthcare innovation, likely leading to increased revenue for companies involved, impacting stock performance positively.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About WVE Stock
What is Wave Life Sciences Ltd.'s (WVE) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Wave Life Sciences Ltd. (WVE) has a median price target of $18.50. The highest price target is $43.00 and the lowest is $12.00.
Is WVE stock a good investment in 2026?
According to current analyst ratings, WVE has 16 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for WVE stock?
Wall Street analysts predict WVE stock could reach $18.50 in the next 12 months. This represents a 208.3% increase from the current price of $6.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Wave Life Sciences Ltd.'s business model?
The company develops RNA-targeted therapeutics using its proprietary PRISM platform, which incorporates various RNA-modulating techniques and insights from genetics. It generates revenue through the advancement of its clinical programs and potential partnerships in the biotechnology sector.
What is the highest forecasted price for WVE Wave Life Sciences Ltd.?
The highest price target for WVE is $43.00 from at , which represents a 616.7% increase from the current price of $6.00.
What is the lowest forecasted price for WVE Wave Life Sciences Ltd.?
The lowest price target for WVE is $12.00 from at , which represents a 100.0% increase from the current price of $6.00.
What is the overall WVE consensus from analysts for Wave Life Sciences Ltd.?
The overall analyst consensus for WVE is bullish. Out of 5 Wall Street analysts, 16 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $18.50.
How accurate are WVE stock price projections?
Stock price projections, including those for Wave Life Sciences Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 9:17 AM UTC